Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

Completed · Phase 2

Conditions studied: Dermatitis, Atopic

In brief

this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.

Key facts

Study ID

NCT02595008

Run by

Sun Pharmaceutical Industries, Inc.

People needed

24

Starts

2015-08-28

Expected to finish

2017-08-25

Last updated by the study team

2018-12-07

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a definite clinical diagnosis of stable atopic dermatitis

You may not qualify if…

• Patient is under the age of 2

Where it is running

• Taro Pharmaceuticals USA Inc. — Hawthorne, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.